Novo Nordisk A/S
NOVC.DE
Deutsche Börse91.40
EUR
-1.85
- -
Novo Nordisk A/S
NOVC.DE
(Deutsche Börse)
Recent
price
91.40
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Novo Nordisk A/S is a leading global healthcare company focused on discovering, developing, manufacturing, and marketing pharmaceutical products and devices for serious chronic diseases, including diabetes care; obesity management; rare blood disorders such as haemophilia; growth hormone therapy; and hormone replacement therapy. The company offers a broad portfolio of innovative therapies, such as GLP-1 receptor agonists including semaglutide marketed as Ozempic and Rybelsus for type 2 diabetes and Wegovy for obesity; insulin products like Levemir, Tresiba, NovoLog, and Novolin R delivered via pens and vials; clotting factors including NovoSeven and NovoEight for haemophilia; and other treatments for rare endocrine disorders. It operates in diabetes and obesity segments primarily, with additional exposure to cardiovascular disease, rare diseases, and emerging therapy areas; serves patients, healthcare providers, and systems worldwide; maintains affiliates in 80 countries; and has strategic production sites in Belgium, Brazil, China, Denmark, France, Italy, and the United States. Founded in 1923 through predecessor companies and formally established via merger in 1989, Novo Nordisk A/S is headquartered in Bagsværd, near Copenhagen, Denmark, with R&D facilities in China, Denmark, the UK, the US, and India; it employs approximately 78,400 people globally, including 33,700 in Denmark and 11,200 in the US. Recent developments include a $2.2 billion collaboration and licensing agreement with U.S. biotech Septerna in May 2025 to develop oral small molecule medicines targeting obesity, type 2 diabetes, and cardio-metabolic disorders, with over $200 million in upfront payments and four planned GPCR programs; positive phase 2 trial results for amycretin in November 2025 showing significant weight loss and HbA1c reduction in type 2 diabetes patients; FDA filing in November 2025 for a higher 7.2 mg dose of Wegovy injection; plans for global workforce reductions of around 9,000 positions, including 5,000 in Denmark, as part of an organizational overhaul to streamline operations and focus on core diabetes and obesity areas; and ongoing production expansion investments of 65 billion DKK announced for 2025.